Zum Inhalt springen

Although the company will continue to pursue „higher-risk, high reward“ drug candidates such as pegilodecakin, these will be a smaller part of the portfolio in the future, said Chief Scientific Officer Daniel Skovronsky. Mr Hancock was today accused of ’sh**ging on the taxpayer‘ after it was revealed he took his mistress to the G7 summit and claims…

Weiterlesen